Table 4. Clinical response of the included studies.
| Study | NFNET | PCN | Insulinomas | Pancreatic adenocarcinomas | Metastasis |
|---|---|---|---|---|---|
| Barthet 2019 | 12/14 | 12/17 | N/A | N/A | N/A |
| Choi 2018 | 5/7 | 1/2 | 1/1 | N/A | N/A |
| Crino 2018 | N/A | N/A | N/A | 7/7 | 1/1 |
| Oleinikov 2019 | 17/18 | N/A | 9/9 | N/A | N/A |
| Pai 2015 | 2/2 | 5/6 | N/A | N/A | N/A |
| Scopelliti 2018 | N/A | N/A | N/A | 10/10 | N/A |
| Song 2016 | N/A | N/A | N/A | 6/6 | N/A |
| Dancour 2019 | N/A | N/A | 8/8 | N/A | N/A |
| Yang 2019 | N/A | N/A | N/A | 8/8 | N/A |
| De la Serna 2018 | 1/3 | 6/6 | N/A | N/A | N/A |
| WPR | 82.2% | 76.8% | 96.6% | 97.1% | N/A |
PCN, pancreatic cystic neoplasm; NFNET, non-functional neuroendocrine tumor; WPR, weighted pooled rate.